Defining the Optimal Respiratory Syncytial Virus Infection Management Strategy: Applying Health Economics to Improve Patient Outcomes

Addressing the Management Challenges of JIA-Associated Uveitis: From Screening to Treatment

A New Paradigm Shift in IBD? Clinical Advances in Applying a Treat-to-Target Strategy

Managing Patients With Overactive Bladder in Canada: Evaluating Recent Evidence

Visit https://www.peervoice.com/FUT860 to view the entire programme with slides. After completing “Spotlight on Multifocal Motor Neuropathy: Strategies to Improve Diagnosis and Treatment”, participants will be able to: Describe the challenges and unmet needs in the diagnosis of multifocal motor neuropathy (MMN); Identify current and emerging techniques for the diagnosis of MMN; and Discuss available and novel treatment options for patients with MMN.

Visit https://www.peervoice.com/CPF860 to view the entire programme with slides. After completing “Managing Risk of Persistent Acute Kidney Injury in the ICU: The RUBY Study”, participants will be able to: Describe the rationale, design, and key findings of a study to identify biomarkers for patients at risk of persistent severe acute kidney injury (AKI); Explain the role of urinary CCL14 as a biomarker for stratifying patients at risk for persistent severe AKI as demonstrated in the study; and Translate the use of biomarkers for management of patients with, or at risk of, persistent severe AKI.

Visit https://www.peervoice.com/PEN860 to view the entire programme with slides. After completing “Treatment Update in Type 2 Diabetes: What’s New, and What Does It Mean for Patients?”, participants will be able to: Summarise updates in practice guidelines for type 2 diabetes (T2DM); Explain rationale for updates, based on clinical evidence and outcomes; and Apply updated strategies for management of T2DM to specific patient scenarios.

Visit https://www.peervoice.com/CVG860 to view the entire programme with slides. After completing “PARPs in Practice in mCRPC: A Look at the Latest Data”, participants will be able to: Describe the most recent clinical data for poly ADP ribose polymerase (PARP) inhibitors for metastatic castration-resistant prostate cancer (mCRPC), including combination regimens; Outline patient-centred strategies to improve quality of life, adherence, and other outcomes in patients with mCRPC; and Identify strategies for optimal monitoring and management of adverse events associated with PARP inhibitors.